Tìm theo
OPC-28326
Thuốc Gốc
Small Molecule
CTHH: C26H38ClN3O3
PTK: 476.051
At low doses, OPC 28326 selectively vasodilates the femoral arterial bed due to its inhibitory action at alpha-2-adrenoceptors while having minimal action on systemic blood pressure, heart rate and coronary, carotid, vertebral, renal, and mesenteric blood flows. It is the only clinical compound with this profile. It is currently being investigated in the treatment of peripheral vascular diseases and Raynaud's syndrome.
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C26H38ClN3O3
Phân tử khối
476.051
Monoisotopic mass
475.260169804
InChI
InChI=1S/C26H35N3O2.ClH.H2O/c1-5-24(30)27-25-19(2)17-22(18-20(25)3)26(31)29-15-12-23(13-16-29)28(4)14-11-21-9-7-6-8-10-21;;/h6-10,17-18,23H,5,11-16H2,1-4H3,(H,27,30);1H;1H2
InChI Key
InChIKey=QRNMKZJPTYRAIL-UHFFFAOYSA-N
IUPAC Name
N-[2,6-dimethyl-4-({4-[methyl(2-phenylethyl)amino]piperidin-1-yl}carbonyl)phenyl]propanamide hydrate hydrochloride
Traditional IUPAC Name
N-[2,6-dimethyl-4-({4-[methyl(2-phenylethyl)amino]piperidin-1-yl}carbonyl)phenyl]propanamide hydrate hydrochloride
SMILES
O.Cl.CCC(=O)NC1=C(C)C=C(C=C1C)C(=O)N1CCC(CC1)N(C)CCC1=CC=CC=C1
logP
4.28
pKa (strongest acidic)
13.85
pKa (Strongest Basic)
9.71
PSA
52.65 Å2
Refractivity
129.32 m3·mol-1
Polarizability
49.91 Å3
Rotatable Bond Count
7
H Bond Acceptor Count
3
H Bond Donor Count
1
Physiological Charge
1
Number of Rings
3
Bioavailability
1
Rule of Five
true
MDDR-Like Rule
true
Dược Lực Học : At low doses, OPC 28326 selectively vasodilates the femoral arterial bed due to its inhibitory action at alpha-2-adrenoceptors while having minimal action on systemic blood pressure, heart rate and coronary, carotid, vertebral, renal, and mesenteric blood flows.
Cơ Chế Tác Dụng : At low doses, OPC 28326 selectively vasodilates the femoral arterial bed due to its inhibitory action at alpha-2-adrenoceptors while having minimal action on systemic blood pressure, heart rate and coronary, carotid, vertebral, renal, and mesenteric blood flows. It is the only clinical compound with this profile. It is currently being investigated in the treatment of peripheral vascular diseases and Raynaud's syndrome. At low doses, OPC 28326 selectively vasodilates the femoral arterial bed due to its inhibitory action at alpha-2C-adrenoceptors. Other studies have also reported selectivity for a-2B-adrenoceptors.
Độc Tính : 10 mg and 40 mg was well tolerated during clinical trials with Raynaud's patients
Chỉ Định : Investigated for use/treatment in peripheral vascular disease and raynaud's disease.
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB05461
PubChem Compound
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=15942713
ChemSpider
http://www.chemspider.com/Chemical-Structure.11252547.html
... loading
... loading